Sermorelin and Ipamorelin Together: What Is Known
Sermorelin and Ipamorelin taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
No studies tested these together (PubMed search: 5 results, 2 Oct 2026).
Side by side
Showing 9 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.
| Field | Sermorelin | Ipamorelin |
|---|---|---|
| Class | GHRH analog | GHRP (ghrelin receptor agonist) |
| Also called | — | ipa, ipam |
| Category | Growth hormone | Growth hormone |
| FDA status | Compounded by prescription | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. | Prohibited by WADA (S2.2.4)Ipamorelin is named as a growth hormone secretagogue in S2.2.4, prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256 | Human RCT evidence, 4 of 4Strongest: International journal of colorectal disease 2014, PMID 25331030 |
| Human studies we summarised | 6 human (1 randomized or controlled) of 9 summarised | 2 human (2 randomized or controlled) of 12 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 9 mg, 15 mg | 2 mg, 5 mg, 10 mg |
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026) |
Sold pre-mixed too
Some vials combine these peptides. The blend calculator shows the dose of each component per draw.
Where sermorelin and ipamorelin come from
In an open-label trial in prepubertal children with GH deficiency, mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr after 6 months of sermorelin.[17]
The only US maker of recombinant GHRH, EMD Serono, announced the discontinuation of Geref in July 2008.[19]
In animal work, ipamorelin was described as the first GHRP-receptor agonist whose selectivity for GH release is similar to GHRH.[20]
Ipamorelin's human pharmacokinetics come from a dose-escalation study in healthy male volunteers, which found a terminal half-life of 2 hours.[13]
The closest thing to a human stack
A retrospective chart review in 105 men on testosterone therapy used GHRP-6, GHRP-2 and SERM (sermorelin), not ipamorelin. Only 14 men met its strict inclusion criteria.[6]
In those 14 men the average IGF-1 rose from 159.5 to 239.0 ng/mL, a hormone marker rather than a body-composition result.[6]
A PubMed search on 2 Oct 2026 for ipamorelin with sermorelin matched 5 records.
Calculated from pubmed query (ipamorelin[tiab]) AND (sermorelin[tiab] OR Geref[tiab]); records matched 5; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date
What the human data cannot show
A review of secretagogues in hypogonadal men calls clinical efficacy data largely lacking for the whole class, sermorelin and ipamorelin included.[21]
The ipamorelin randomised trial cited reported no significant difference from placebo in its key and secondary efficacy analyses.[14]
Common questions
Sermorelin vs ipamorelin: which is better?
No trial compares them. Sermorelin has paediatric growth data and a discontinued brand; ipamorelin has no approved product and one randomised trial with no significant difference from placebo.[14]
Is sermorelin still FDA approved?
Its only FDA records are for Geref, listed as discontinued, and no currently marketed approved sermorelin product was found.[22]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 5Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
- 6Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
- 7Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
- 8PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
- 12Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 13Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
- 14Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
- 15The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
- 16PubMed search: (ipamorelin[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
- 18PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?The Journal of clinical endocrinology and metabolism · 2009PMID 19509104Accessed 2 Oct 2026
- 20Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
- 21Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.Translational andrology and urology · 2020PMID 32257855Accessed 2 Oct 2026
- 22Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.